Stated Choice Methods in Long-Acting and Extended-Release HIV Technologies: A Scoping Review of Methodological Practices and Translational Utility

Abstract Purpose of Review Long-acting and extended-release (LA/ER) technologies are expanding options for HIV prevention and treatment, but their population impact will depend on whether products and delivery models align with the priorities and constraints of intended users and providers. We reviewed how stated choice methods have been designed, analyzed, and used to generate implementation-relevant evidence for LA/ER technologies. Recent Findings Fifty peer-reviewed studies published from 2020 to 2026 met inclusion criteria. Most examined HIV prevention (74%), enrolled end-users only (92%), and used discrete choice experiments or related variants (86%). Stakeholder-informed attribute sources were reported in 94%, but only 40% described dedicated, study-specific qualitative or advisory processes. Preference heterogeneity (94%), service-delivery attributes (80%), and structural access barriers (94%) were common. Only 22% included a respondent-specific status-quo comparator, 60% reported comprehension testing, and 4% achieved moderate-to-high representativeness. Although 84% examined pipeline-aligned attributes, reporting did not establish whether those attributes remained modifiable at the relevant product-lifecycle stage. Only four studies included providers, and treatment-preference research was concentrated in high-income settings. Summary Methodological sophistication does not ensure translational utility. Stated choice studies should align their attributes, sampling, and choice architecture with the decision-maker, the product’s lifecycle stage, and the decisions still open to change. As products mature, research should prioritize actionable delivery, access, and health-system decisions and validate preferences against product experience and observed behavior.

Authors

Institutions

Publication Details

Journal
Current HIV/AIDS Reports
Published
2026-11-16
DOI
https://doi.org/10.1007/s11904-026-00804-0
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Stated Choice Methods in Long-Acting and Extended-Release HIV Technologies: A Scoping Review of Methodological Practices and Translational Utility

Christine Tagliaferri Rael, Charles W. Flexner, Alexandra M. Minnis, Sarit A. Golub et al.
Current HIV/AIDS Reports
HIV/AIDS Research and Interventions
article

Stated Choice Methods in Long-Acting and Extended-Release HIV Technologies: A Scoping Review of Methodological Practices and Translational Utility

Christine Tagliaferri Rael, Charles W. Flexner, Alexandra M. Minnis, Sarit A. Golub, Kate Bergmann Carey, Karine Dubé, Sybil Hosek, Willey Lin, José A. Bauermeister, Douglas Krakower, Cody Bangcaya
article en

Abstract

Abstract Purpose of Review Long-acting and extended-release (LA/ER) technologies are expanding options for HIV prevention and treatment, but their population impact will depend on whether products and delivery models align with the priorities and constraints of intended users and providers. We reviewed how stated choice methods have been designed, analyzed, and used to generate implementation-relevant evidence for LA/ER technologies. Recent Findings Fifty peer-reviewed studies published from 2020 to 2026 met inclusion criteria. Most examined HIV prevention (74%), enrolled end-users only (92%), and used discrete choice experiments or related variants (86%). Stakeholder-informed attribute sources were reported in 94%, but only 40% described dedicated, study-specific qualitative or advisory processes. Preference heterogeneity (94%), service-delivery attributes (80%), and structural access barriers (94%) were common. Only 22% included a respondent-specific status-quo comparator, 60% reported comprehension testing, and 4% achieved moderate-to-high representativeness. Although 84% examined pipeline-aligned attributes, reporting did not establish whether those attributes remained modifiable at the relevant product-lifecycle stage. Only four studies included providers, and treatment-preference research was concentrated in high-income settings. Summary Methodological sophistication does not ensure translational utility. Stated choice studies should align their attributes, sampling, and choice architecture with the decision-maker, the product’s lifecycle stage, and the decisions still open to change. As products mature, research should prioritize actionable delivery, access, and health-system decisions and validate preferences against product experience and observed behavior.

Current HIV/AIDS ReportsVol. 23(1)
National Institutes of Health (US), Beth Israel Deaconess Medical Center (US), Johns Hopkins University (US), City University of New York (US), RTI International (US), University of Illinois Chicago (US), University of Colorado Anschutz Medical Campus (US), University of Pennsylvania (US)
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon